[Skip to Navigation]
July 1988

A Combination of Levobunolol and Dipivefrin for the Treatment of Glaucoma

Author Affiliations

From the Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville (Dr Allen); The Wilmer Eye Institute, The John Hopkins Hospital (Dr Robin), and Sinai Hospital (Drs Robin and Kaplan), Baltimore; Allergan Pharmaceuticals Inc, Irvine, Calif (Dr Novack and Mr Lue); and the University of California at Irvine (Dr Novack). Dr Long is in private practice in Gretna, La.

Arch Ophthalmol. 1988;106(7):904-907. doi:10.1001/archopht.1988.01060140050022

• This double-masked prospective study compared the ocular hypotensive efficacy and the safety of 0.5% and 1% levobunolol hydrochloride with 0.5% timolol maleate when each was administered topically twice daily in combination with 0.1% dipivefrin hydrochloride. Forty-three patients whose intraocular pressure was previously controlled by concomitant treatment with timolol and dipivefrin were randomly assigned to receive 0.5% or 1% levobunolol and 0.1% dipivefrin, or to continue to receive 0.5% timolol and 0.1% dipivefrin for three months. In the groups receiving levobunolol and dipivefrin concurrently, continued intraocular pressure control was achieved equal to that attained with timolol and dipivefrin before study entry. We concluded that concomitant treatment with levobunolol and dipivefrin is equal in both efficacy and safety to concomitant treatment with timolol and dipivefrin.

Add or change institution